Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKC202 in Combination With Limertinib Versus Platinum-based Chemotherapy in NSCLC
NCT07109531Phase 3Recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 3 trial of askc202 in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
askc202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07109531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109531.